June 15, 2023
Akeylink Biotechnolog
Akeylink Biotechnolog is a company focusing on the research and development of innovative drugs in the field of antiviral and liver diseases. It was established in November 2021 and is headquartered in Hongqiao Business District, Shanghai. The controlling shareholder Guangshengtang (stock code: 300436) It is the first listed private pharmaceutical manufacturing enterprise in Fujian Province. The company’s current research pipeline covers anti-new coronavirus, hepatitis B cure drugs, anti-hepatic fibrosis drugs, and cancer-targeted drugs. Currently, 6 product pipelines under research have entered the clinical stage. The preclinical and clinical data of the broad-spectrum anti-new coronavirus oral 3CL inhibitor GST-HG171 have shown excellent antiviral efficacy and safety, and it is expected to become a leading 3CL protease inhibitor of its kind. The “Dengfeng Project” focuses on the cure of hepatitis B and deploys core protein inhibitors and surface antigen inhibitors. It is currently in clinical phase I or II, and the progress is leading. GST-HG161 is a cMet inhibitor, which has been shown to have inhibitory effects on a variety of solid tumors in phase I clinical trials. “
福建广生中霖生物科技有限公司是一家专注于抗病毒和肝病疾病领域创新药物研发公司，成立于2021年11月，总部在上海市虹桥商务区，控股股东广生堂（股票代码：300436）是福建省首家民营医药制造上市企业。公司目前在研管线涵盖了抗新冠病毒、乙肝治愈类药物、抗肝纤维化药物以及癌症靶向药物，目前在研6个产品管线均进入临床阶段。广谱抗新冠病毒口服3CL抑制剂GST-HG171临床前、临床数据显示了优异的抗病毒药效和安全性，有望成为同类领先的3CL蛋白酶抑制剂。“登峰计划”围绕乙肝治愈布局核心蛋白抑制剂和表面抗原抑制剂，目前处于临床I或II期，进度领先。GST-HG161为cMet抑制剂，临床I期显示对多种实体瘤具有抑制效果。”
StoneWise
StoneWise uses AI to quickly identify and process a variety of structured R&D data, and combines the domain knowledge of pharmaceutical R&D experts to build a 100 million-level ultra-high-throughput molecular screening system, a multi-dimensional molecular generation system and a molecular optimization system based on a mapping database. Systematization enables faster and better new drug discovery. Based on the understanding of drug research and development and strong engineering capabilities, Stonemind has built an efficient and practical AI drug molecule design platform StoneMIND® (Master of Intelligent Novel Design), which transforms the tools for different R&D links into software or SaaS, and cooperates with drug developers perform information extraction, knowledge mining, and drug molecule design.
望石智慧利用AI快速识别处理繁多结构化的研发数据，结合医药研发专家的领域知识，构建了亿级别的超高通量分子筛选系统、多维度分子生成系统和基于映射数据库的分子优化系统，体系化赋能更快、更好的新药发现。基于对药物研发的理解和强大的工程化能力，望石智慧构建了高效实用的AI药物分子设计平台StoneMIND® (Master of Intelligent Novel Design)，将服务不同研发环节的工具软件化或SaaS化，配合药物研发人员进行信息提取、知识挖掘和药物分子设计。
Starna Therapeutics
Starna Therapeutics was founded in August 2021. With the mission of “serving life and health”, the company focuses on extrahepatic delivery technology and is committed to developing innovative drugs with mRNA as the core to solve unmet clinical needs. The company has the world’s leading delivery technology with independent intellectual property rights to achieve tissue-specific RNA drug delivery. It has completed hundreds of millions of yuan in financing with the participation of many well-known institutions, and established a research and development center of over 4,000 square meters in Suzhou Biomedical Industrial Park and pilot production base.
星锐医药(Starna Therapeutics)创立于2021年8月，公司以“服务生命健康”为使命，聚焦肝外递送技术，致力于开发以mRNA为核心的创新药物，解决未被满足的临床需求。公司拥有全球领先的具有自主知识产权的递送技术，实现组织特异性的RNA药物递送，已完成由多家知名机构参与的数亿元融资，并在苏州生物医药产业园建立了超4000平米的研发和中试生产基地。
PharmaSolux Biotech (Wuxi) Co., Ltd.
PharmaSolux Biotech (Wuxi) Co., Ltd. is a biotech company that focuses on the development of world-leading tumor therapeutic drugs. Professor Lai Hung-sen, founder and chairman, has decades of research experience in computational chemistry, biochemistry, and peptide drug design & synthesis. He has also been deeply involved in developing several new drug inventions that have entered the stage of human clinical trials. The company’s core team members all have more than decades of pharmaceutical industry experience. PharmaSolux has a rich product pipeline with a small-molecule immuno-oncology drug that has won an award from The National Cancer Institute in the US. This product was also highly praised by the Chief of Fox Chase Cancer Center. In addition, the company has cooperated with the world’s top tumor research institutions and scientists to develop rich and solid pre-clinical platforms that can be applied for multiple indications. Three R&D platforms have been deployed. The PROTAC platform and the PDC platform are two successful cases of new drugs. The SMDC is an emerging drug coupling technology. All products are FIC or BIC, with global rights. And the company focuses on the global market, has rich patent portfolios and strong patent protection.
致谨生物科技（无锡）有限公司是一家专注于开发世界前沿的肿瘤治疗药物的公司。董事长赖宏森教授有数十年计算化学、生物化学、多肽药物设计合成等领域专长和经验，多个新药发明已进入人体临床试验阶段；公司核心成员均拥有超过数十年的行业从业经验。具有丰富的产品管线。明星产品，小分子免疫肿瘤药物获得了美国NCI的奖项；与世界顶级的肿瘤研究机构和科学家合作，受到了如Fox Chase癌症中心主任的高度赞誉。丰富、坚实的临床前验证，可拓展多项适应症。布局了3项研发平台，PROTAC平台；PDC平台，该平台已有两个新药的成功案例；SMDC是一种新兴的药物偶联技术。所有产品均为FIC或BIC，具有全球权益，公司关注于全球市场。拥有丰富的专利组合及强有力的专利保护。
Staidson biopharmaceuticals
Staidson biopharmaceuticals is an innovation-driven full-chain biopharmaceutical company. It was established in 2002 and listed on the Shenzhen Stock Exchange in China in 2011. Stadson focuses on research and development, from the initial target verification to the commercialization of a single product with a domestic sales peak of over 100 million. The company has independently developed a national first-class new drug – mouse nerve growth factor “Su Taisheng” for injection, and a domestic bowel cleansing and constipation drug with two indications for both bowel cleansing and constipation – polyethylene glycol electrolyte powder “Shutaiqing” “. The company’s main products have been identified as “National Torch Program Products”, “Beijing High-tech Achievement Transformation Project”, “National Biomedical High-tech Industrialization Demonstration Project” and “Beijing Independent Innovation Products”, and won the Beijing Municipal Science and Technology Progress Three Prizes.
舒泰神公司是一家以创新为驱动的全链条生物制药公司。 它成立于2002年，2011年在中国深圳证券交易所上市。 Stadson专注于研发，从最初的靶点验证，到单品国内销售高峰过亿的商业化。公司自主研制开发了国家一类新药——注射用鼠神经生长因子“苏肽生”和国内同时具有清肠和便秘两个适应症的清肠便秘类药物——聚乙二醇电解质散剂“舒泰清”。公司主要产品被认定为“国家火炬计划产品”、“北京市高新技术成果转化项目”、“国家生物医药高技术产业化示范工程项目”及“北京市自主创新产品”，获北京市科技进步三等奖。
SalubrisBio
SalubrisBio is a clinical-stage biotechnology company dedicated to discovering and developing complex biologics for cardiovascular, oncology, and neurodegenerative diseases. SalubrisBio was founded in August 2016 as a wholly-owned subsidiary of the China-based pharmaceutical company,Shenzhen Salubris Pharmaceuticals Co. Ltd. Headquartered in the US, SalubrisBio reflects Shenzhen Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market and retains the core philosophy of developing therapeutics for large patient populations with significant unmet information.
信立泰是一家临床阶段的生物技术公司，致力于发现和开发用于心血管、肿瘤和神经退行性疾病的复杂生物制剂。SalubrisBio成立于2016年8月，是中国制药公司深圳Salubris Pharmaceuticals Co. Ltd.的全资子公司。SalubrisBio总部位于美国，体现了深圳Salubris Pharmaceuticals致力于创新和拓展全球市场，并保留了核心为需求未得到满足的大量患者开发治疗方法的理念。
Evive Biotech
Evive Biotech, a subsidiary of Yifan Pharmaceutical, is a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide. They leverage their proprietary technology platforms to advance a series of innovative drug candidates for oncology, inflammatory and metabolic diseases. Founded in 2004, we currently have operations in the US, EU, Singapore, and China. Evive adopts a holistic approach for drug development, combining exceptional preclinical and clinical research capabilities with our world-class in-house manufacturer and regulatory expertise. Ryzneuta™ (F-627) is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) intended to treat chemotherapy induced neutropenia (CIN) in patients with cancer.
亿一生物科技是一帆药业的子公司，是一家致力于为全球患者开发新型生物疗法的全球性生物制药公司。他们利用自己的专有技术平台推进一系列针对肿瘤、炎症和代谢疾病的创新候选药物。公司成立于2004年，目前在美国、欧盟、新加坡和中国设有拆分机构。Evive采用整体方法进行药物开发，将卓越的临床前和临床研究能力与世界一流的内部生产和监管专业知识相结合。Ryzneuta™(F-627)是一种新型的长效粒细胞集落刺激因子(G-CSF)，用于治疗癌症患者化疗诱导的中性粒细胞减少症(CIN)。
Jacobio Pharma
Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people’s health. The pipeline revolves around novel molecular targets on six major signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.
加科思药业(1167.HK)致力于为患者提供突破性治疗方案。公司在研项目围绕KRAS、肿瘤免疫、肿瘤代谢、P53、RB、MYC六大肿瘤信号通路布局，核心项目以全球前三为目标。公司的愿景是与合作伙伴携手共进，成为全球认可的药物研发领导者。加科思的实验室坐落于中国北京、上海和美国波士顿，拥有诱导变构药物发现平台和iADC药物研发平台。
Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMiceTM HiTS Platform). As of December 31, 2022, 34 therapeutic antibody development/out-licensing/transfer agreements and 17 RenMiceTM licensing agreements have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen’s pipeline is comprised of 11 core assets, with partnerships established for 4 out of 6 total clinical assets.
百奥赛图（股票代码：02315.HK）是一家创新技术驱动新药研发的国际性生物技术公司，致力于成为全球新药发源地，以专注技术创新、持续新药产出、守护人类健康为使命。基于百奥赛图自主研发并拥有完全独立知识产权的全人抗体RenMice®平台（RenMab®、RenLite®和RenNano®小鼠），将单抗、双抗和纳米抗体开发技术平台、动物体内药效筛选平台、强大的临床开发能力有机整合在一起，形成了独具特色、涵盖药物研发全流程的新药研发能力。百奥赛图正在对1000多个潜在可成药的靶点进行规模化药物开发（“千鼠万抗™”计划），截至2022年12月31日，百奥赛图已签署了34项药物合作开发/授权/转让协议并与包括多家MNC在内的17家企业达成RenMice®平台授权。同时百奥赛图建立了由11项在研药物组成的核心管线；就6项临床资产中的4项与外部合作方建立了项目合作关系。
Antengene Pharmaceuticals
Antengene Pharmaceuticals Limited is a leading R&D-driven biopharmaceutical company that has entered the commercialization stage. With the vision of “Boundless doctors, sustainable innovation”, Antengene focuses on the early R&D, clinical research, drug production and commercialization of the first-in-class and best-in-class therapies in the field of blood and solid tumors, and is committed to providing breakthrough therapies that improve the quality of life of patients worldwide.Since 2017, Antengene has established a R&D pipeline with 9 oncology drug assets from clinical extension to commercialization stage, of which 6 products have global rights, and 3 products have rights including Greater China. Asia-Pacific interests. Currently, Sivio® (Selinexor Tablets) has been approved for marketing as a new drug in mainland China, Taiwan, South Korea, Singapore and Australia.
德琪医药有限公司是一家以研发为驱动，并已进入商业化阶段的生物制药领先企业。以“医者无疆，创新永续”为愿景，德琪医药专注于血液及实体肿瘤领域的同类首款和同类最优疗法的早期研发、临床研究、药物生产及商业化，致力于通过提供突破性疗法，改善全球患者生活质量。 自2017年以来，德琪医药现已建立起一条拥有9款从临床延展至商业化阶段的肿瘤药物资产的研发管线，其中，6款产品具有全球权益，3款产品具有包括大中华区在内的亚太权益。目前，希维奥®（塞利尼索片）已获得中国大陆、中国台湾、韩国、新加坡和澳大利亚的新药上市批准。
Bioplus Life Sciences
Bioplus Life Sciences is a research driven company, continually evolving and aspires to improve products and service quality through the utilization of the latest technology combined with extensive research and experimentation on food ingredients and Nutraceutical products.
Bioplus Life Sciences是一家以研究为导向的公司，通过利用最新技术，结合对食品配料和营养保健品的广泛研究和实验，不断发展并提高产品和服务质量。 Bioplus Life Sciences拥有一个设备齐全的化学合成实验室，重点研究领域为碳水化合物化学、功能表面活性剂、树状大分子和天然产物。Bioplus Life Sciences的生物技术实验室配备了处理微生物菌株的设施，通过微生物发酵开发产品。
BioToChina.org 